CD96 and cancer: Chemoresistance is a primary factor associated with poor prognosis in patients with cancer and is closely associated with specific features of the CSCs in these patients.[22, 26, 27] To determine whether CD96 participates in chemoresistance in BCSCs, we enriched MCF‐7 and SKBR3 BCSCs and treated them with docetaxel or cisplatin in the presence or absence of a CD96‐blocking antibody in vitro.